If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Alberto Sobrero is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 2 Similar Profiles
Colorectal Neoplasms Medicine & Life Sciences
oxaliplatin Medicine & Life Sciences
Fluorouracil Medicine & Life Sciences
Colonic Neoplasms Medicine & Life Sciences
irinotecan Medicine & Life Sciences
Leucovorin Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Disease-Free Survival Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1978 2019

Aflibercept Plus FOLFIRI for Second-line Treatment of Metastatic Colorectal Cancer: Observations from the Global Aflibercept Safety and Health-Related Quality-of-Life Program (ASQoP)

Riechelmann, R. P., Srimuninnimit, V., Bordonaro, R., Kavan, P., Di Bartolomeo, M., Maiello, E., Cicin, I., García-Alfonso, P., Chau, I., Fedyanin, M. Y., Martos, C. F., Ter-Ovanesov, M., Peeters, M., Ko, Y. J., Yalcin, S., Karthaus, M., Aparicio, J., Heinemann, V., Picard, P., Bury, D. & 2 others, Drea, E. & Sobrero, A., Jan 1 2019, In : Clinical Colorectal Cancer.

Research output: Contribution to journalArticle

Open Access
Colorectal Neoplasms
irinotecan
Quality of Life
Safety
Leucovorin
5 Citations (Scopus)
Colorectal Neoplasms
Randomized Controlled Trials
GDC-0973
regorafenib
MPDL3280A
5 Citations (Scopus)

HER2 Amplification and Anti-EGFR Sensitivity in Advanced Colorectal Cancer

Bregni, G., Sciallero, S. & Sobrero, A., Jan 1 2019, In : JAMA oncology.

Research output: Contribution to journalArticle

Maximising clinical benefit with adequate patient management beyond the second line in mCRC

Argiles, G., Arnold, D., Prager, G., Sobrero, A. F. & Van Cutsem, E., May 1 2019, In : ESMO Open. 4, 2, e000495.

Research output: Contribution to journalReview article

Open Access
Colorectal Neoplasms
Trifluridine
Quality of Life
Therapeutics
Foot
3 Citations (Scopus)

Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: The Italian expanded access program

Verzoni, E., Cartenì, G., Cortesi, E., Giannarelli, D., De Giglio, A., Sabbatini, R., Buti, S., Rossetti, S., Cognetti, F., Rastelli, F., Sobrero, A., Turci, D., Sternberg, C. N., Porta, C., Cappuzzo, F., Tortora, G., Tassinari, D., Panni, S., Pazzola, A., Surico, G. & 3 others, Raimondi, A., De Giorgi, U. & Procopio, G., Apr 3 2019, In : Journal for ImmunoTherapy of Cancer. 7, 1, 99.

Research output: Contribution to journalArticle

Open Access
Renal Cell Carcinoma
Drug-Related Side Effects and Adverse Reactions
Safety
Survival
Logistic Models